Gallium Scan Vs PET Scan: When Is Each Used?

In a gallium scan vs PET scan comparison, PET is generally the more commonly used modern imaging test for evaluating many cancers because it can provide detailed whole-body information within a shorter imaging process. Gallium imaging still has specific roles, particularly for certain infections, inflammation, lymphoma assessment, and specialized gallium PET studies.

Gallium Scan vs PET Scan: Side-by-Side Comparison

A gallium scan and a positron emission tomography (PET) scan are both nuclear medicine imaging tests. They involve an injection of a radiotracer, a substance that gives off a small amount of radiation and can be detected by a specialized camera. The tracer collects differently in tissues depending on processes such as inflammation, infection, or tumor activity.

The key distinction is not simply which test is “better.” It is which tracer and imaging method best answer a clinician’s question. A conventional gallium scan often uses gallium-67 and is now used less often than PET for many cancer evaluations. PET can use several tracers, most commonly fluorodeoxyglucose (FDG), a glucose-like substance that may accumulate in metabolically active cells.

Feature	Conventional gallium scan	PET scan
Common tracer	Gallium-67 citrate	Usually FDG; other tracers may be selected
Main uses	Selected infections, inflammatory disorders, some lymphomas and other specific situations	Many cancers, staging, treatment response, recurrence assessment, and selected heart or brain conditions
Timing	Images are often taken 24 to 72 hours after injection	Images are commonly taken about an hour after tracer injection
Image detail	Often less detailed, though SPECT/CT may improve localization	Usually high-resolution functional imaging, commonly combined with CT or MRI
Limitations	Slower process and uptake can occur with infection or inflammation as well as cancer	Some tumors have low FDG uptake; inflammation and infection can also cause uptake

Many PET examinations are performed as PET/CT, combining information about tissue activity with detailed anatomical images. PET/MRI may be used in selected circumstances. The imaging team will explain preparation instructions, including whether fasting is needed, based on the specific tracer being used.

How a Clinician Tells the Tests Apart

Clinicians choose between gallium imaging and PET by starting with the medical question rather than the name of the scan. They consider the person’s symptoms, physical examination, blood test results, known diagnosis, prior imaging, treatment history, and whether the goal is to identify disease, map its extent, assess response to treatment, or investigate a possible recurrence.

For example, FDG PET/CT is often considered when a clinician needs to assess many types of active cancer throughout the body. However, FDG is not cancer-specific. Healing tissues, infection, autoimmune inflammation, and normal organs such as the brain can show tracer uptake. Radiologists and nuclear medicine physicians interpret the scan alongside CT or MRI findings and the person’s clinical history.

A conventional gallium scan may be considered when particular inflammatory or infectious processes are suspected or when another test is not suitable or has not answered the question. In some cases, gallium imaging is paired with SPECT/CT, which can help pinpoint abnormal uptake more accurately within the body.

It is also important to distinguish a gallium-67 scan from gallium-68 PET. Gallium-68 is a tracer label used with PET technology, not the same examination as a traditional gallium scan. Gallium-68 can be attached to specialized compounds that target particular receptors on tumor cells, making it valuable for selected cancers.

What Are the Differences Between a Gallium Scan and PET for Detecting Cancer?

For detecting cancer, a PET scan is generally used more often than a conventional gallium scan. FDG PET/CT can show areas with increased glucose use, which may help identify many cancers, determine whether cancer has spread, assess how treatment is working, and investigate possible recurrence. It is particularly useful when its findings will change treatment planning.

A conventional gallium scan can detect some cancers because gallium may collect in certain tumors, especially some lymphomas. However, it is less commonly the first imaging choice for cancer today because PET usually offers faster imaging and more detailed localization. Gallium uptake is also not specific to cancer and may occur with infection or inflammation.

The cancer type matters greatly. Some slow-growing tumors and cancers with naturally low FDG uptake may not be well evaluated with standard FDG PET. In these settings, an alternative PET tracer, MRI, CT, ultrasound, or another targeted test may provide more useful information. For people being assessed for lymphoma, the imaging approach is individualized according to the lymphoma subtype and treatment plan.

An abnormal scan result does not establish a cancer diagnosis on its own. A clinician may recommend targeted imaging, laboratory testing, monitoring over time, or a biopsy to identify the cause of an abnormal area safely and accurately.

What Is the Most Accurate Scan for Cancer?

There is no single scan that is most accurate for every cancer. Accuracy depends on the cancer type, its size and location, how quickly it is growing, whether it has spread, and the exact clinical question. A test that is excellent for one tumor may be less useful for another.

For many cancers, PET/CT is highly informative because it combines metabolic and anatomical information. Yet CT and MRI can be better for defining anatomy in certain regions, such as the brain, liver, pelvis, or spinal cord. Ultrasound is often valuable for some organs and for guiding biopsies. A doctor may use more than one imaging method because each contributes different information.

Specialized PET tracers can improve assessment of particular cancers. For instance, receptor-targeted PET can be more appropriate than FDG PET for some neuroendocrine tumors, while other tracers may be selected for prostate cancer. The most appropriate examination is therefore the one matched to the suspected diagnosis and the decision that needs to be made.

Imaging findings are interpreted by trained specialists and integrated with pathology, symptoms, and other test results. A tissue biopsy remains necessary in many situations to confirm a cancer type before treatment begins.

Can a Gallium Scan Detect Cancer?

Yes, a gallium scan can detect areas that may be associated with cancer, but it cannot reliably diagnose cancer by itself. Traditional gallium-67 imaging may show uptake in some malignancies, including certain lymphomas, because gallium can accumulate in tissues with increased inflammation, blood flow, or cellular activity.

However, uptake may also occur in noncancerous conditions such as infection, inflammation, recent surgery, or healing tissue. Conversely, some cancers may not show significant gallium uptake. For these reasons, a gallium scan result is interpreted as one part of a broader clinical assessment rather than a final answer.

If a scan identifies an area of concern, the next step depends on where it is located and how it appears. A clinician may recommend CT, MRI, PET/CT, repeat imaging, specialist evaluation, or a biopsy. It is helpful for patients to ask what question the scan was intended to answer and how its result will affect the next step in care.

Can a Gallium PET Scan Detect Neuroendocrine Tumors?

Yes. A gallium-68 PET scan using a somatostatin receptor-targeting tracer can be very useful for detecting many well-differentiated neuroendocrine tumors. These tumors often carry somatostatin receptors on their cell surface. The specialized tracer binds to these receptors, allowing the PET scanner to identify areas of uptake.

This is different from a conventional gallium-67 scan. Gallium-68 somatostatin receptor PET/CT can help locate a primary tumor, evaluate whether disease has spread, clarify uncertain findings on other imaging, and support treatment planning. It may also help determine whether a person could be suitable for certain receptor-targeted therapies.

Not all neuroendocrine tumors behave the same way. Higher-grade or more rapidly growing tumors may be evaluated with FDG PET as well, because they can have different metabolic characteristics. The treating team may recommend one or both approaches based on tumor grade, pathology findings, symptoms, and previous imaging.

People with suspected or confirmed neuroendocrine tumors benefit from assessment by clinicians experienced in this diverse group of conditions. Results should be reviewed in the context of pathology and other scans rather than interpreted in isolation.

What to Expect and How to Prepare

Preparation depends on the test and tracer. For many FDG PET scans, patients are asked to fast for several hours and avoid strenuous exercise beforehand because blood sugar and muscle activity can affect tracer distribution. Gallium-67 scan preparation may differ, and imaging may occur on more than one day after the injection.

Before either examination, patients should tell the imaging team about pregnancy, breastfeeding, diabetes, kidney problems, allergies, current medicines, recent infections, recent surgery, and prior imaging studies. Most radiotracers leave the body naturally over time. The team may advise drinking fluids and urinating regularly after the test, unless another medical condition limits fluid intake.

The injection itself is usually brief. During scanning, the person needs to lie still while the camera obtains images. The scan is generally painless, although remaining still or lying flat may be uncomfortable for some people. Sedation is not routinely required, but patients should mention claustrophobia, pain, or mobility concerns in advance.

A result is usually reported by a nuclear medicine physician or radiologist to the referring clinician. Patients should avoid trying to interpret terms such as “uptake” or “activity” without medical guidance, as these descriptions do not automatically mean cancer.

When to Seek Medical Care

Patients should contact their clinician promptly if they have new or worsening symptoms that led to imaging being considered, such as an unexplained lump, persistent pain, unexplained weight change, prolonged fever, drenching night sweats, unusual bleeding, or a persistent change in bowel, urinary, breathing, or neurological function. These symptoms have many possible causes, and timely assessment helps determine the right next step.

After a scan, patients should discuss the results with the clinician who ordered it, especially if the report recommends additional tests. Urgent medical care is appropriate for severe chest pain, sudden weakness or difficulty speaking, severe shortness of breath, uncontrolled bleeding, or other sudden serious symptoms.

For people seeking coordinated diagnostic evaluation, Acıbadem Health Point’s multidisciplinary specialists and JCI-accredited hospitals diagnose and treat a range of complex conditions for international patients. The most suitable imaging pathway should always be determined by a qualified clinician based on individual needs.

Frequently asked questions